{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:30:53Z","timestamp":1794709853408,"version":"4.9.1"},"reference-count":18,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"unspecified","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,6,27]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Timely recognition of immune checkpoint immune-related neurological adverse events (irNAEs) is critical given their potential severity, yet remains challenging due to limited clinical experience. This study investigates clinical presentation and management of irNAEs from a neurological perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively identified all patients treated with immune checkpoint inhibitors (ICIs) at Erasmus MC Cancer Institute, Rotterdam, The Netherlands between 2017 and 2024. Patient records were analysed by a neurologist for clinical and treatment of irNAE post-ICI initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 3176 ICI-treated patients, irNAE was diagnosed in 76 cases (2.4%). Peripheral syndromes occurred in 55 (70%), central in 21 (30%) patients. Classification into distinct disease entities was challenging due to remarkable overlap in affected neurological structures. Median onset of irNAE was 8 weeks after ICI initiation (range 1\u2013104 weeks); 70% developed within 18 weeks. IrNAE-related mortality was 13%, observed only in the first 18 weeks. Fewer non-small cell lung cancer patients developed irNAE (OR, 0.36; 95% CI 0.16 to 0.8; p=0.012) compared with other tumour types. Males (OR, 1.78; 95% CI 1.1 to 2.90; p=0.019) and PD1\/CTLA4 combination therapy (OR 2.1, 95% CI 1.28 to 3.46, p=0.004) were associated with increased irNAE incidence. Glucocorticoids were given in 64% of patients; 14% received immunosuppressive therapy beyond steroids. Treatment response varied widely, both clinically and temporally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This retrospective single-centre study confirms irNAEs are infrequent complications of ICI. The distinct symptom profile, with substantial overlap within affected neurological structures, underscores the need for neurological expertise in irNAE care. While most develop within 18 weeks of treatment, late-onset cases occur. Mortality occurred only in early-onset cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2026-001591","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:20:13Z","timestamp":1785496813000},"page":"e001591","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Neurological complications induced by checkpoint inhibitors: characterising the clinical spectra"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2888-3798","authenticated-orcid":false,"given":"Anne Merel","family":"van Wylick","sequence":"first","affiliation":[{"name":"Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"van den Bent","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-2458","authenticated-orcid":false,"given":"Bart C","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus MC Universitair Medisch Centrum Rotterdam, Rotterdam, The Netherlands"},{"name":"Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Titulaer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus MC Universitair Medisch Centrum Rotterdam, Rotterdam, The Netherlands"},{"name":"Academic Center for Neuro-inflammatory disorders, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Kerstens","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus MC Universitair Medisch Centrum Rotterdam, Rotterdam, The Netherlands"},{"name":"Academic Center for Neuro-inflammatory disorders, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Brusse","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus MC Universitair Medisch Centrum Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H J","family":"Mathijssen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-7902","authenticated-orcid":false,"given":"Daphne W","family":"Dumoulin","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Erasmus Medical Center Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A M","family":"van der Veldt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Geurts","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands"},{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"2026073104200732000_8.2.e001591.1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102962","article-title":"Adjuvant immunotherapy for melanoma patients: progress and opportunities","volume":"9","author":"Sussman","year":"2024","journal-title":"ESMO Open"},{"key":"2026073104200732000_8.2.e001591.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.05.029"},{"key":"2026073104200732000_8.2.e001591.3","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxrep.2025.102033","article-title":"Immune checkpoint inhibitors: From friend to foe","volume":"14","author":"Rajak","year":"2025","journal-title":"Toxicol Rep"},{"key":"2026073104200732000_8.2.e001591.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2026073104200732000_8.2.e001591.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2026073104200732000_8.2.e001591.6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2022.07.015","article-title":"Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study","volume":"174","author":"Basak","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026073104200732000_8.2.e001591.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9"},{"key":"2026073104200732000_8.2.e001591.8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2026073104200732000_8.2.e001591.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034497"},{"key":"2026073104200732000_8.2.e001591.10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026073104200732000_8.2.e001591.11","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931"},{"key":"2026073104200732000_8.2.e001591.12","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"2026073104200732000_8.2.e001591.13","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2017162","article-title":"Association between immune-related adverse event timing and treatment outcomes","volume":"11","author":"Hsiehchen","year":"2022","journal-title":"Oncoimmunology"},{"key":"2026073104200732000_8.2.e001591.14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359"},{"key":"2026073104200732000_8.2.e001591.15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"2026073104200732000_8.2.e001591.16","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01395-7"},{"key":"2026073104200732000_8.2.e001591.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026073104200732000_8.2.e001591.18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-335998"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2026-001591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:20:15Z","timestamp":1785496815000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2026-001591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,7,31]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjno-2026-001591"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2026-001591","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}